Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2022—Roche launched its Avenio Edge System, an all-in-one preanalytical platform that is designed to minimize manual touchpoints and includes ready-to-load reagents, validated protocols, onboard capabilities, and intuitive software to manage next-generation sequencing sample workflows.
April 2022—Roche announced the launch of the Cobas Pulse system, the company’s newest generation of connected POC solutions for professional blood glucose management, in select countries accepting the CE mark.
April 2022—Tribun Health announced it won a 2022 “Best in KLAS” award for digital pathology in Europe. The Best in KLAS report from KLAS Research recognizes software and services companies that excel in helping health care professionals improve patient care.
April 2022—Alcor Scientific is partnering with Chicago-based health care investor Water Street Healthcare Partners. Water Street will invest in Alcor’s research and development initiatives, product portfolio, and international expansion. Alcor has appointed Jim Post as chief executive officer to lead its next phase of innovation and growth.
April 2022—Verichem Laboratories offers two multilevel, protein-based test kits of clinical reference materials for the calibration or calibration verification of lithium assays. Intended for use with direct and indirect ion-selective electrodes, colorimetric assays, and flame photometers, the Electrolyte Standard Kit and Serum ISE Standard Kit contain NIST-verified gravimetric concentrations for lithium. The liquid-stable, ready-to-use materials can also be used for quality control monitoring, method evaluations, post-maintenance testing, and routine troubleshooting.
January 2022—Death investigators are tasked with the responsibility of providing irrefutable and accurate determinations in the cause and manner of death in a timely fashion for ongoing investigations. Outcomes of any death may be revealed by the specimens submitted for toxicology analysis. The conundrum of ample opinions is that there is no “one size fits all” when selecting appropriate specimens. Human nature tends to rely on traditional approaches for the collection, processing, and reporting of results because it’s easier to stay status quo. However, with drug overdose deaths increasing, reports are further delayed, causing an influx of backlogged cases. To assist with these issues, our laboratory developed an economical, time-efficient, safe, and less-invasive collection method that delivers real-time results within 24 to 48 hours, accelerating the autopsy process and the ability to close cases expeditiously.
January 2022—Roche launched its Cobas 5800 system in countries accepting the CE mark. The real-time PCR molecular testing solution is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation, and delivery to the laboratory information system. The single module enables a walkaway time of up to eight hours.
January 2022—Seegene unveiled the Novaplex SARS-CoV-2 Variants VII assay for research use only. The assay identifies positive COVID-19 cases and distinguishes between alpha, beta, gamma, delta, and omicron and its stealth version. The RT-PCR test targets five analytes including the RdRP gene and three omicron S-gene mutations, E484A, N501Y, HV69/70 deletion. It also targets endogenous internal controls, which serve as a control to verify specimen validity.
December 2021—Hardy Diagnostics has released its HardyChrom Candida plus auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species. This medium allows for the identification of C. albicans, C. tropicalis, and C. krusei, and the presumptive identification of C. glabrata.
December 2021—Bio-Rad Laboratories launched an enhanced version of its Liquichek Diabetes Control. The liquid, human whole-blood–based control comes in three levels to address the HbA1c precision monitoring needs of a wide range of test methods.
